Drug Trial Radar · NCT05934214
EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database
Last checked: Nov 20, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
141,630
Actual
Start
Jan 1, 2023
Primary completion
Dec 31, 2023
Study completion Feb 29, 2024
Sponsor
- Lead sponsor
- Groupe Hospitalier Pitie-SalpetriereAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institut Curie
- First posted
- Jul 6, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an observational, retrospective pharmacovigilance study based on reports registered and transmitted in VigiBase®, the WHO's international database. This study includes all reports identified as exposure to an ICI and suspect of inducing adverse drug reaction. The aim of the study is to characterize immune-related adverse reactions associated with immune-checkpoint inhibitors, particularly their time-to-onset, co-occurence, factors associate with their over-report and fatality.
Conditions
- Cancer
- Immune-related Adverse Event
- Immune Checkpoint Inhibitor-Related Myocarditis
Interventions
Immune checkpoint inhibitorDrug
Reports associated with an an Immune checkpoint inhibitor with a status of "Suspect" or "Interacting" ICI will include the following list of FDA-apporved ICIs: nivolumab, pembrolizumab, cemiplimab, dostarlimab, durvalumab, atezolizumab, avelumab, ipilimumab, tremelimumab, relatlimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Factors associated with an increased rate of fatality among reports with an immune-related adverse event (irAE).Time frame: any report prior to january 2023
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM.
Paris, France
CIC Paris-Est / Institut Curie
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.